Article
Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation.
Journal of cancer research and clinical oncology - 1 Aug 2022
Luo Yung-Hung, Liu Han, Wampfler Jason A, Tazelaar Henry D, Li Yalun, Peikert Tobias, Liu Dan, Leventakos Konstantinos, Chen Yuh-Min, Yang Yanan, Chiou Shih-Hwa, Yang Ping
Abstract excerpt
BACKGROUND: The efficacy of osimertinib in previously EGFR-TKI-treated NSCLC without identification of T790M mutational status remains unclear in real-world practice. PATIENTS AND METHODS: 417 patients had stage III-IV NSCLC harboring EGFR mutation and 154 out of 417 patients receiving osimertinib as ≥ second-line EGFR-TKI were identified. The time to treatment failure and risk of death were analyzed. RESULTS:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.